MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1002/1878-0261.70050

Медицинская библиотека · Molecular oncology · 2025

The anticancer effect of the HDAC inhibitor belinostat is enhanced by inhibitors of Bcl-xL or Mcl-1 in ovarian cancer.

Thomine Cécilia, Guillemot Sterenn, Weiswald Louis-Bastien, Florent Romane, Abeilard Edwige, Giffard Florence, Brotin Emilie, Briand Mélanie, Dolivet Enora, Poulain Laurent, Villedieu Marie

СтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

Identifying innovative therapeutic strategies is crucial to improve clinical management of ovarian cancer. Previously, we showed that ovarian cancer cell apoptosis can be triggered by inhibiting the anti-apoptotic proteins Bcl-xL and Mcl-1 and/or by inducing their pro-apoptotic partners Bim, Puma, and Noxa. The expression of these pro-apoptotic proteins can be hindered by excessive histone deacetylation, resulting from HDAC overexpression. This study aimed to evaluate whether belinostat, an FDA-approved pan-HDAC inhibitor, could increase Bim, Puma, and/or Noxa expression and induce ovarian cancer cell death, either alone or in combination with strategies targeting Bcl-xL or Mcl-1. Belinostat exerted a cytostatic effect and, at higher concentrations, an apoptotic effect in SKOV3 and IGROV1-R10 ovarian cancer cells. It induced a concentration-dependent increase in Bim, Puma, and Noxa protein expression, while partially repressing that of Bcl-xL. Inhibition of Bcl-xL sensitized both cell lines to belinostat, as did inhibition of Mcl-1 in IGROV1-R10 cells. Interestingly, belinostat's anticancer activity was also enhanced by inhibitors of Bcl-xL or Mcl-1 in patient-derived tumor organoids. This study therefore positions belinostat-based strategies as promising therapies for ovarian cancer.

Для цитирования: Thomine Cécilia, Guillemot Sterenn, Weiswald Louis-Bastien, Florent Romane, Abeilard Edwige, Giffard Florence, Brotin Emilie, Briand Mélanie, Dolivet Enora, Poulain Laurent, Villedieu Marie. The anticancer effect of the HDAC inhibitor belinostat is enhanced by inhibitors of Bcl-xL or Mcl-1 in ovarian cancer.. Molecular oncology. 2025. DOI: 10.1002/1878-0261.70050.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.